Major companies in the pemphigus vulgaris field:
Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Chemistry, Inc., Argenx, Rho Federation Systems Division, Inc.
Pemphigus vulgaris market overview
(Albany, USA) – DelveInsight's report “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecasts – 2034” provides an in-depth assessment of Pemphigus vulgaris, covering historical and projected epidemiological trends, treatment practices, and market trends in the US, EU4 (Germany, France, Italy, Spain), UK, and Japan.
This comprehensive analysis focuses on current treatment approaches, emerging treatment options, individual drug market shares, and expected market size trends from 2020 to 2034. The study further assesses market drivers, challenges, unmet clinical needs, and potential opportunities in the pemphigus vulgaris field.
? Click here to gain detailed insights into Pemphigus vulgaris market trends, treatment pathways, and drug adoption. Pemphigus vulgaris market forecast
Key points from the Pemphigus vulgaris market report:
Pemphigus vulgaris market is projected to witness steady growth at a notable CAGR throughout the forecast period (2020-2034).
The US market alone was worth about $2,000. $250 million in 2023.
January 2025: Cabaletta Bio shared positive updates from a Phase 1/2 study evaluating autologous CART therapy (DSG3-CAART and CABA-201) in patients with active pemphigus vulgaris.
September 2024: IRIS RD disclosed the results of a study evaluating the combination of rituximab and AB-101 in autoimmune diseases, including pemphigus vulgaris.
August 2024: The first patient was treated in a basket IIT trial with AlloNK® and rituximab for autoimmune diseases including PV, RA, GPA/MPA, and SLE, highlighting the community's access to innovative treatments.
Epidemiological highlights:
In 2023, the United States will have approximately40,000PV pieces, is predicted to rise by 2034.
In 2022,14,000 cases diagnosed The most notable and most prevalent in the United States are:Age group 60-69 years old, the number of cases in the 0-17 group is minimal.
Severity breakdown (2022, USA):6,000 miles、 4,000 medium level、 4,300 severe cases case.
Of the EU4+UK,Germany The highest prevalence of diagnosis of8,000 pieces, followed by the UK. France The lowest value was reported to be around 3,000.
Above 7MM, womenHigh prevalence of diagnosed compared with men throughout the study period (2020-2034).
With the increasing number of innovative medicines in development and growing recognition, the pemphigus vulgaris market is poised for significant evolution and expansion.
Pemphigus vulgaris – disease overview
Pemphigus vulgaris (PV) is a rare, life-threatening autoimmune disease that causes blisters on the skin and mucous membranes. This occurs when the immune system produces autoantibodies against desmoglein, an important adhesion protein in the skin, which causes cells to separate and form blisters.
PV most commonly occurs in middle-aged and elderly people and often begins with painful oral lesions before progressing to the skin. Diagnosis of PV includes clinical evaluation, biopsy, immunofluorescence, and detection of autoantibodies. Treatment primarily includes corticosteroids and immunosuppressants such as rituximab, azathioprine, and mycophenolate mofetil.
The advent of biologics and targeted therapies is reshaping the treatment paradigm, leading to fewer long-term side effects and improved treatment outcomes. However, long-term monitoring remains essential to manage recurrence and treatment-related risks.
? Get a Free Sample of Pemphigus Vulgaris Market Forecast and Size Report: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
Market drivers and challenges
Main driving force:
Increasing disease awareness and improving diagnosis
Increased prevalence of autoimmune diseases
Advances in biologics (e.g. rituximab, CAART, AlloNK®)
Continuing research and development and positive regulatory momentum
barrier:
High cost of biological treatment
Diagnostic challenges due to disease rarity
Access restrictions in specific regions
Side effects of long-term immunosuppressive therapy
Small patient pool hinders large-scale clinical trials
Despite these hurdles, the overall market is expected to benefit from increased investment in innovation and expanded access to healthcare.
Epidemiology breakdown of pemphigus vulgaris (2020–2034)
This report provides a detailed epidemiological snapshot of the entire 7MM, including:
Overall PV penetration rate
Prevalence by severity
Prevalence by gender
Temporary diagnosed cases and chronic diagnosed cases
? For detailed forecasts, download the full epidemiology report. Epidemiological prediction of pemphigus vulgaris
Pipeline insights and drug intake
Adoption analysis tracks the adoption of both recent and upcoming treatments and measures market penetration, patient share, and sales trends.
Pipeline therapies and developers:
PRN1008 – Principia Biopharma
mycophenolate mofetil - Genentech Co., Ltd.
KC706 – Kemia Co., Ltd.
Efgarti Gimod PH20 SC – Argenx
mRNA-1273 (Moderna) – Rho Federal Systems Division Ltd.
Recent strategic moves, licensing agreements, clinical milestones, and corporate collaborations are also analyzed.
? Discover key pipeline therapies that have the potential to dominate future market share. Treatment of pemphigus vulgaris
Report scope and scope
Forecast period: 2020 ~ 2034
Target area: US, EU5 (Germany, France, Italy, Spain, UK), Japan
Major companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Kemia, argenx, Rho Federal Systems Division
Main treatments: PRN1008, mycophenolate mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273
Analysis tools: SWOT, PESTLE, BCG Matrix, Porter's Five Forces
Additional focus: Unmet needs, KOL insights, market access, and reimbursement landscape
? Click here for company-level analysis, clinical pipeline reviews, and market access insights. Clinical trials and market evaluation of pemphigus vulgaris
Table of Contents Overview
introduction
executive summary
SWOT analysis
Patient Share Overview
market snapshot
Background of the disease
Insights into epidemiology
national epidemiology
Current treatment status
unmet needs
new treatment
market forecast
Market analysis by country
Market access and redemption
market drivers
market barriers
appendix
research methods
About DelveInsight
Disclaimer
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm focused on life sciences. We provide end-to-end support to pharmaceutical companies and provide strategic insights to enhance performance and competitiveness.
Contact Information
Kanishk
Email-kkumar@delveinsight.com
